单位：[1]Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China[2]Chinese Univ Hong Kong, Med Data Analyt Ctr, Hong Kong, Peoples R China[3]Univ Melbourne, St Vincents Hosp Melbourne, Dept Gastroenterol, Melbourne, Vic, Australia[4]Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[5]Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Peoples R China[6]Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China[7]Univ Indonesia, Dr Cipto Mangunkusumo Natl Gen Hosp, Dept Gastroenterol, Jakarta, Indonesia[8]Univ Indonesia, Dr Cipto Mangunkusumo Natl Gen Hosp, Dept Internal Med, Div Trop Med & Infect, Jakarta, Indonesia[9]Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan[10]Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi, Japan[11]Univ Malaya, Dept Med, Kuala Lumpur, Malaysia[12]Univ Auckland, Auckland City Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand[13]Metropolitan Med Ctr, Dept Gastroenterol, Manila, Philippines[14]Natl Univ Singapore, Dept Med, Singapore, Singapore[15]Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea[16]Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan[17]Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatitis Ctr, Kaohsiung, Taiwan[18]Prince Songkla Univ, Fac Med, NKC Inst Gastroenterol & Hepatol, Dept Gastroenterol, Hat Yai, Thailand
The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic are discussed.
第一作者单位：[1]Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China[2]Chinese Univ Hong Kong, Med Data Analyt Ctr, Hong Kong, Peoples R China
通讯作者：
通讯机构：[1]Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China[2]Chinese Univ Hong Kong, Med Data Analyt Ctr, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714)：
Wong Grace Lai-Hung,Wong Vincent Wai-Sun,Thompson Alex,et al.Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement[J].LANCET GASTROENTEROLOGY & HEPATOLOGY.2020,5(8):776-787.doi:10.1016/S2468-1253(20)30190-4.
APA：
Wong, Grace Lai-Hung,Wong, Vincent Wai-Sun,Thompson, Alex,Jia, Jidong,Hou, Jinlin...&Chan, Henry Lik-Yuen.(2020).Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement.LANCET GASTROENTEROLOGY & HEPATOLOGY,5,(8)
MLA：
Wong, Grace Lai-Hung,et al."Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement".LANCET GASTROENTEROLOGY & HEPATOLOGY 5..8(2020):776-787
医学